MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
0.7414
-0.0339
-4.37%
After Hours: 0.7125 -0.0289 -3.90% 19:07 06/05 EDT
OPEN
0.7960
PREV CLOSE
0.7753
HIGH
0.8050
LOW
0.7300
VOLUME
108.95K
TURNOVER
--
52 WEEK HIGH
2.220
52 WEEK LOW
0.5480
MARKET CAP
9.18M
P/E (TTM)
-0.4809
1D
5D
1M
3M
1Y
5Y
1D
Pantginis Reiterates Buy on APR-1051 Developer, Keeps $1.20 Price Target After Encouraging ASCO Data and Superior Safety Profile
TipRanks · 5d ago
Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors
Benzinga · 6d ago
Aprea Therapeutics reports early Phase 1 activity for WEE1 inhibitor APR-1051 in advanced solid tumors at ASCO 2026
PUBT · 6d ago
Weekly Report: what happened at APRE last week (0525-0529)?
Weekly Report · 6d ago
Weekly Report: what happened at APRE last week (0518-0522)?
Weekly Report · 05/25 09:08
Weekly Report: what happened at APRE last week (0511-0515)?
Weekly Report · 05/18 09:08
APREA THERAPEUTICS - FILES FOR RESALE OF UP TO 5.5 MLN SHARES BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 05/15 20:39
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target
TipRanks · 05/14 20:15
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Webull offers Aprea Therapeutics Inc stock information, including NASDAQ: APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.